{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:25Z","timestamp":1793043085441,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"publisher","award":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"],"award-info":[{"award-number":["Katherine McCleary Research Fund and K. Edward Jacobi Research Partners Fund"]}],"id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009269","name":"Amyloidosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001695","name":"International Waldenstrom's Macroglobulinemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001695","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41375-019-0667-6","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T07:04:00Z","timestamp":1574924640000},"page":"1373-1382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen D.","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ramirez-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"667_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.1993.11.5.914","volume":"11","author":"MA Gertz","year":"1993","unstructured":"Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom\u2019s macroglobulinemia. J Clin Oncol. 1993;11:914\u201320.","journal-title":"J Clin Oncol"},{"key":"667_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3816\/CLML.2011.n.034","volume":"11","author":"MA Gertz","year":"2011","unstructured":"Gertz MA, Buadi FK, Hayman SR. IgM amyloidosis: clinical features in therapeutic outcomes. Clin Lymphoma Myeloma Leuk. 2011;11:146\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"667_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3816\/CLM.2009.n.021","volume":"9","author":"G Palladini","year":"2009","unstructured":"Palladini G, Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A, et al. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma. 2009;9:80\u20133.","journal-title":"Clin Lymphoma Myeloma"},{"key":"667_CR4","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2008-02-138156","volume":"112","author":"AD Wechalekar","year":"2008","unstructured":"Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood. 2008;112:4009\u201316.","journal-title":"Blood"},{"key":"667_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","volume":"33","author":"S Zanwar","year":"2019","unstructured":"Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, et al. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019;33:790\u20134.","journal-title":"Leukemia"},{"key":"667_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.beha.2016.08.013","volume":"29","author":"P Milani","year":"2016","unstructured":"Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. Best Pract Res Clin Haematol. 2016;29:241\u20138.","journal-title":"Best Pract Res Clin Haematol"},{"key":"667_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MD.0b13e31816c43b6","volume":"87","author":"B Terrier","year":"2008","unstructured":"Terrier B, Jaccard A, Harousseau JL, Delarue R, Tournilhac O, Hunault-Berger M, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine. 2008;87:99\u2013109.","journal-title":"Medicine"},{"key":"667_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/13506129.2015.1092433","volume":"22","author":"M Sissoko","year":"2015","unstructured":"Sissoko M, Sanchorawala V, Seldin D, Sworder B, Angelino K, Broce M, et al. Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid. 2015;22:229\u201335.","journal-title":"Amyloid"},{"key":"667_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","volume":"34","author":"S Sachchithanantham","year":"2016","unstructured":"Sachchithanantham S, Roussel M, Palladini G, Klersy C, Mahmood S, Venner CP, et al. European Collaborative Study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis. J Clin Oncol. 2016;34:2037\u201345.","journal-title":"J Clin Oncol"},{"key":"667_CR10","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/leu.2016.369","volume":"31","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31:1562\u20139.","journal-title":"Leukemia"},{"key":"667_CR11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","volume":"33","author":"T Bochtler","year":"2015","unstructured":"Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33:1371\u20138.","journal-title":"J Clin Oncol"},{"key":"667_CR12","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","volume":"123","author":"SP Treon","year":"2014","unstructured":"Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791\u20136.","journal-title":"Blood"},{"key":"667_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N. Engl J Med. 2015;372:1430\u201340.","journal-title":"N. Engl J Med"},{"key":"667_CR14","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1182\/blood-2016-02-702035","volume":"127","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty R, Novak AJ, Ansell SM, Muchtar E, Kapoor P, Hayman SR, et al. First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood. 2016;127:2936\u20138.","journal-title":"Blood"},{"key":"667_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2015-10-674895","volume":"127","author":"B Thakral","year":"2016","unstructured":"Thakral B, Kanagal-Shamanna R, Systemic AL. amyloidosis associated with Waldenstrom macroglobulinemia: an unusual presenting complication. Blood. 2016;127:168.","journal-title":"Blood"},{"key":"667_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"667_CR17","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"667_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325\u201332.","journal-title":"Blood"},{"key":"667_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130:625\u201331.","journal-title":"Blood"},{"key":"667_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","volume":"130","author":"T Dittrich","year":"2017","unstructured":"Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130:632\u201342.","journal-title":"Blood"},{"key":"667_CR21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/leu.2017.286","volume":"32","author":"S Sidana","year":"2018","unstructured":"Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018;32:729\u201335.","journal-title":"Leukemia"},{"key":"667_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160:171\u20136.","journal-title":"Br J Haematol"},{"key":"667_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/bjh.13303","volume":"169","author":"FG Rosado","year":"2015","unstructured":"Rosado FG, Morice WG, He R, Howard MT, Timm M, McPhail ED. Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process. Br J Haematol. 2015;169:368\u201376.","journal-title":"Br J Haematol"},{"key":"667_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/modpathol.2009.34","volume":"22","author":"WG Morice","year":"2009","unstructured":"Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom\u2019s macroglobulinemia. Mod Pathol. 2009;22:807\u201316.","journal-title":"Mod Pathol"},{"key":"667_CR25","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/10428194.2017.1410885","volume":"59","author":"M Shi","year":"2018","unstructured":"Shi M, Ternus JA, Ketterling RP, Jevremovic D, McPhail ED. Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms. Leuk Lymphoma. 2018;59:1913\u20139.","journal-title":"Leuk Lymphoma"},{"key":"667_CR26","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569\u201375.","journal-title":"Blood"},{"key":"667_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.15","volume":"6","author":"M Binder","year":"2016","unstructured":"Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 2016;6:e401.","journal-title":"Blood Cancer J"},{"key":"667_CR28","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957\u20139.","journal-title":"Blood"},{"key":"667_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-09-806463","volume":"131","author":"T Pika","year":"2018","unstructured":"Pika T, Hegenbart U, Flodrova P, Maier B, Kimmich C, Schonland SO. First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. Blood. 2018;131:368\u201371.","journal-title":"Blood"},{"key":"667_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom\u2019s macroglobulinemia. N. Engl J Med. 2012;367:826\u201333.","journal-title":"N. Engl J Med"},{"issue":"15_suppl","key":"667_CR31","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1200\/JCO.2017.35.15_suppl.8048","volume":"35","author":"S Sidana","year":"2017","unstructured":"Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi F, Lacy M, et al. Factors predicting organ response in light chain amyloidosis (AL). J Clin Oncol. 2017;35 15_suppl:8048.","journal-title":"J Clin Oncol"},{"key":"667_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41375-018-0258-y","volume":"33","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia. 2019;33:527\u201331.","journal-title":"Leukemia"},{"key":"667_CR33","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29:3389\u201395.","journal-title":"J Clin Oncol"},{"key":"667_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.15044","volume":"180","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Thompson DS, Boccia RV, Miletello G, Lipman A, Flora D, et al. Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. Br J Haematol. 2018;180:365\u201373.","journal-title":"Br J Haematol"},{"key":"667_CR35","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/j.bbmt.2018.12.003","volume":"25","author":"MH Sidiqi","year":"2019","unstructured":"Sidiqi MH, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, et al. Autologous stem cell transplant for IgM-associated amyloid light-chain amyloidosis. Biol Blood Marrow Transplant. 2019;25:e108\u201311.","journal-title":"Biol Blood Marrow Transplant"},{"key":"667_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3816\/CLM.2009.n.020","volume":"9","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Hayman SR, Buadi FK. Transplantation for IgM amyloidosis and IgM myeloma. Clin Lymphoma Myeloma. 2009;9:77\u20139.","journal-title":"Clin Lymphoma Myeloma"},{"key":"667_CR37","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/bmt.2014.113","volume":"49","author":"MA Marzolini","year":"2014","unstructured":"Marzolini MA, Thomson KJ, Dorman J, D\u2019Sa S. BEAM-conditioned autologous SCT improves the quality of response in Waldenstrom\u2019s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre\u2019s 10-year experience. Bone Marrow Transplant. 2014;49:1231\u20132.","journal-title":"Bone Marrow Transplant"},{"key":"667_CR38","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","volume":"28","author":"C Kyriakou","year":"2010","unstructured":"Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:2227\u201332.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0667-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0667-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0667-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:38:43Z","timestamp":1684604323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0667-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0667-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"26 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SS: Consultancy: Janssen. AD: research funding from Celgene, Takeda, Prothena, Janssen, Pfizer, Alnylam, and GSK. PK: research funding from Celgene and Takeda. MQL: research funding from Celgene. SKK: research funding and membership on an entity\u2019s Board of Directors or advisory committees: AbbVie, Celgene, Janssen, KITE, and Merck. Membership on an entity\u2019s Board of Directors or advisory committees: Oncopeptides and Takeda. Research funding from Novartis and Roche. MAG: honoraria\/consultancy from Ionis, Alnylam, Prothena, Celgene, Janssen, Spectrum, Annexon, Apellis, Amgen, Medscape, Abbvie, Research to Practice, Physicians Education Resource, and Teva. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}